PROVO, Utah--(BUSINESS WIRE)--GeNOsys, Inc. (OTCBB: GNYS) today announced they are sponsoring a Phase I safety trial in collaboration with Nitric Solutions Inc. GeNOsys will be testing their patented nitric oxide generator and nitric oxide producing formula for safety and effectiveness in treating disease. In a parallel study Nitric Solutions will be testing the efficacy of their prophilactic nitric oxide producing formula NitrisolTM. The studies will be conducted in a Canadian government research facility by Dr. Kevin Kane; results are expected to be available within 30 days. GeNOsys will demonstrate that nitric oxide can be safely administered with the generator in compliance with FDA guidelines. Nitric Solutions Inc. will show the antimicrobial effectiveness of NitrisolTM in the treatment of H1N1.
